ICCC Key Statistics, Chart & Performance
The current stock price of ICCC is 6.24 USD. In the past month the price increased by 13.87%. In the past year, price increased by 20.23%.
ICCC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About ICCC
Company Profile
ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 70 full-time employees. The firm is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. The company operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Company Info
IMMUCELL CORP
56 Evergreen Drive
Portland MAINE 04103 US
CEO: Michael F. Brigham
Employees: 70
Phone: 12078782770
IMMUCELL CORP / ICCC FAQ
Can you describe the business of IMMUCELL CORP?
ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 70 full-time employees. The firm is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. The company operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
What is the stock price of IMMUCELL CORP today?
The current stock price of ICCC is 6.24 USD. The price decreased by -1.73% in the last trading session.
What is the dividend status of IMMUCELL CORP?
ICCC does not pay a dividend.
What is the ChartMill technical and fundamental rating of ICCC stock?
ICCC has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the PE ratio for ICCC stock?
The PE ratio for IMMUCELL CORP (ICCC) is 24. This is based on the reported non-GAAP earnings per share of 0.26 and the current share price of 6.24 USD.
What is the Short Interest ratio of IMMUCELL CORP (ICCC) stock?
The outstanding short interest for IMMUCELL CORP (ICCC) is 0.25% of its float.
ICCC Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ICCC. When comparing the yearly performance of all stocks, ICCC turns out to be only a medium performer in the overall market: it outperformed 54.6% of all stocks.
ICCC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ICCC. Both the profitability and the financial health of ICCC get a neutral evaluation. Nothing too spectacular is happening here.
ICCC Financial Highlights
Over the last trailing twelve months ICCC reported a non-GAAP Earnings per Share(EPS) of 0.26. The EPS increased by 152% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.37% | ||
| ROA | 5.08% | ||
| ROE | 7.8% | ||
| Debt/Equity | 0.27 |